speb/financial-data huggingface dataset:
AARTECH.NS income_statement (annual, 2026-03-31) — Operating Revenue: 408842000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 174645000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 31770375.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 31770375.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 14229000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 14229000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 5907000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 5907000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 192178000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 192178000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 1700000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 1305000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 1305000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 13091000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -6944000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 71044000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 18930000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Other Properties: 44650000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 44650000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 102543000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 102543000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: -12171000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Payables: 79535000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Payables: 79535000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Pension And Employee Benefit Expense: 1788000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Pretax Income: 61792000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 16256000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 0.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -5260000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -4907000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 224931000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 123310000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 5198000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 1279000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 35770000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 1195000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Share Issued: 31770375.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 31770375.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Short Term Debt Issuance: 201000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Special Income Charges: 0.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 12171000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 351030000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 351030000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 351030000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 351030000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 4868400.00
AARTECH.NS income_statement (annual, 2026-03-31) — Tax Provision: 22087000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 10164000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.36
AARTECH.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
AARTECH.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 2334000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 2334000.00
AARTECH.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -5766000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Assets: 506292000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 506292000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 351030000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 351030000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Debt: 56170000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 56170000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 350633000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 350633000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Total Expenses: 352693000.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 161085000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 155659000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 155659000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 80827000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 80827000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 6581000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 6581000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 12922000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 12922000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 0.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 12171000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 12171000.00
AARTECH.NS balance_sheet (annual, 2026-03-31) — Working Capital: 276389000.00
AARTECH.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 276389000.00
AARTECH.NS income_statement (annual, 2026-03-31) — Write Off: 0.00
AARTECH.NS income_statement (quarterly, 2026-03-31) — Write Off: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -4790636000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 36198000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -42784000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Amortization: 407000.00
AARTIDRUGS.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 407000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Available For Sale Securities: 194804000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 92600000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Basic EPS: 22.14
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 1920680000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 12842000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 203279000.00
AARTIDRUGS.NS cash_flow (annual, 2022-03-31) — Common Stock Issuance: 0.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 92600000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Diluted EPS: 22.14
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 7181000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 1255428000.00
AARTIDRUGS.NS cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of PPE: -169000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 132289000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 7541804000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Interest Income: 7169000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 7169000.00
AARTIDRUGS.NS cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 934595000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 8792291000.00
AARTIDRUGS.NS cash_flow (annual, 2022-03-31) — Net Other Investing Changes: -100000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 1699000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 284354000.00
AARTIDRUGS.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 56198000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Other Payable: 615706000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 37135000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 704339000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 2322532000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 600000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 7181000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 8787496000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 683648000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 815937000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 31598000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Tradeand Other Payables Non Current: 93865000.00
AARTIDRUGS.NS balance_sheet (annual, 2022-03-31) — Work In Process: 1625266000.00
AARTIDRUGS.NS income_statement (annual, 2022-03-31) — Write Off: 16865000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — +Operating Expense: 2166196000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — +Total Revenue: 27055678000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 4925321000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 8648392000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -5259565000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 36198000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -39562000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Amortization: 648000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 648000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 187992000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 92600000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Basic EPS: 17.97
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 216120000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 1932448000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -1648178000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 23953000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 926000000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 75034000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 83829000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -94013000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 8795000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 75034000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 58218000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Change In Payable: -277366000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -944223000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -1163371000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -141086000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Common Stock: 926000000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 11924347000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 7556000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Common Stock Payments: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 2104830000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 22225987000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Current Assets: 14917882000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 19922000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Current Debt: 4018419000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 4038341000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 9494771000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 43700000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Depreciation: 502593000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 503241000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 503242000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 502594000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 92600000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Diluted EPS: 17.97
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 1663088000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 5769000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Dividends Received Cfi: 11000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — EBIT: 2574753000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — EBITDA: 3077995000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — End Cash Position: 75034000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 165422000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 1265324000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -314966000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -1123000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -1112000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 137867000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 243291000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 8687954000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 14118723000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Gross Profit: 4829691000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Interest Expense: 332932000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 332932000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Interest Income: 6992000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 6992000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -361863000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 6992000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Inventory: 5162910000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 17989539000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -1639720000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 187992000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 7556000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 1158382000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 937665000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 4031000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 2046773000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 2050804000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 1158382000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -558611000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 72677000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 9121916000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Minority Interest: 2333000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Minority Interests: -484000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 7556000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Net Debt: 5990158000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -13074000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Income: 1663088000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 1663088000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 1663572000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 1663088000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 1663088000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 2241821000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 1663572000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Interest Income: -364388000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: 0.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 613741000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 599771000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -364388000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Other Financing Charges: 1000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: 1000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Net PPE: 8859158000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -1646724000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 13970000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 11681056000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 1699000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 709681000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 30347000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 5607000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 3093300000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Normalized Income: 1674445840.50
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 1333212000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Operating Income: 2663495000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Operating Revenue: 27055678000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 92600000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 900500000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 445200000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 10998300000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 243291000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 47807000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 354871000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 236700000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: -33000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: -42003000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 6239000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Payable: 294017000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Properties: 21864000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 65716000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 8795000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Payables: 5298353000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 43673000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 951266000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Pretax Income: 2241821000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 7594000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: 0.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -1648178000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 2121605000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 22225987000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 503241000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 600000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -558611000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 5769000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 10205349000.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 1454000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 698067000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 835934000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Share Issued: 92600000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Special Income Charges: -15305000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 11924347000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 11681056000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -3947159.50
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Tax Provision: 578249000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.26
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 0.00
AARTIDRUGS.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -596748000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Assets: 24213982000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 13971120000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Debt: 6089145000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 11926680000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Total Expenses: 24392183000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 12287302000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 9296048000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 2792531000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 38448000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 73246000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -15305000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -15305000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Tradeand Other Payables Non Current: 122661000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Work In Process: 1728174000.00
AARTIDRUGS.NS balance_sheet (annual, 2023-03-31) — Working Capital: 5423111000.00
AARTIDRUGS.NS income_statement (annual, 2023-03-31) — Write Off: 15305000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — +Operating Expense: 5858500000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — +Total Revenue: 25088708000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 4496083000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 7045536000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -5746009000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 42848000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -29673000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Amortization: 3989000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 3989000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 199741000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 91935000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Basic EPS: 18.56
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 75034000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 2257136000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -2263345000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Capital Expenditure Reported: -2263345000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 18636000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 919350000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 67427000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 89285000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -92673000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 67427000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 342458000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Change In Payable: -925312000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 1610703000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 1027849000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -7607000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Common Stock: 919350000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 12815485000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Common Stock Payments: -598500000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 2440310000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 20240055000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Current Assets: 13207199000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 9496000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Current Debt: 2870872000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 2880368000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 7955427000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 29500000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Depreciation: 510484000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 514473000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 514472000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 510483000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 91935000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Diluted EPS: 18.56
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 1714182000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 5030000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 11000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — EBIT: 2690428000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — EBITDA: 3204901000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — End Cash Position: 67427000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -1360331000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 1490379000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 1325887000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: 1823000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 141835000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 368190000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 7075209000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 16285411000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Gross Profit: 8508600000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Interest Expense: 335150000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 335200000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Interest Income: 24955000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 24955000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -313083000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 24955000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Inventory: 4858923000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 18439649000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -2236508000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 199741000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 1481850000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 937665000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 9140000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 2753292000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 2762432000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 1481850000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -459360000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 27400000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 10632795000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 4058000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Minority Interests: -1725000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: -598500000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Net Debt: 5556737000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -18266000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Income: 1714182000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 1714182000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 1715907000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 1714182000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 1714182000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 2355300000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 1715907000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Interest Income: -353925000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -222845000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: 1022490000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: -353925000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: -133230000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Other Investing Changes: -1000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Net PPE: 10539402000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: 1872000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: -1245335000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 12447295000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 1699000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 757070000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 27410000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 8994000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 3228610000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Normalized Income: 1731454006.50
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 3589232000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Operating Income: 2777035000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Operating Revenue: 25088708000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 91935000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 1092700000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 2000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 11896200000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 368190000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 51932000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 310195000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 197000000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Non Current Liabilities: -1000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: -44135000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 5865000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Payable: 297669000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Properties: 17505000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 77374000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 21858000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Other Special Charges: 1834000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Payables: 4830758000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 29543000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 1131051000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Pretax Income: 2355278000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: 18958000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -2263345000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 2035343000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 20240055000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 514473000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 600000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -459360000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Repurchase Of Capital Stock: -598500000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 5030000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 11552484000.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 1872000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 576887000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 718722000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Share Issued: 91935000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Special Income Charges: -23709000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 12815485000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 12447295000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -6436993.50
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Tax Provision: 639371000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.27
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 0.00
AARTIDRUGS.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -623995000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Assets: 24323580000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 15568777000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Debt: 5642800000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 12819543000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Total Expenses: 22311673000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 11504037000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 11116327000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 3548610000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 43730000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 31976000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -23709000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -23709000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Work In Process: 1281269000.00
AARTIDRUGS.NS balance_sheet (annual, 2024-03-31) — Working Capital: 5251772000.00
AARTIDRUGS.NS income_statement (annual, 2024-03-31) — Write Off: 21875000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 3976200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 6825500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 19900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 113400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 295600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 12774000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 2986900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 12558800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 9100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 2999700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 3008800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 7811100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 56000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 22400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 11340600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 4700000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 18655100000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 199700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 10800000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 2881400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 2892200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 27400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 3890000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Net Debt: 5767700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 11340600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 12751600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 785200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 91270000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 715500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 574900000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 11861300000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 174000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Liabilities: 10000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 8353700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 2600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 182200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Payables: 3976200000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 91270000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 12774000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 12751600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Taxes Receivable: 19600000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 24295500000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 15655400000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 5901000000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 12777890000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 11517610000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 11736700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 3706510000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 4747700000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — +Operating Expense: 6136500000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 1627800000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — +Total Revenue: 23870300000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 6767600000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 4339375000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 4339375000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 7511758000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 7511758000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -6267694000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 49498000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 49498000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -55879000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -55879000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 960000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 224127000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 224127000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 91270000.00
AARTIDRUGS.NS income_statement (annual, 2025-03-31) — Basic EPS: 18.35
AARTIDRUGS.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 6.88
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 67400000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 2418784000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 2418784000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -1771600000.00
AARTIDRUGS.NS cash_flow (annual, 2025-03-31) — Capital Expenditure Reported: -1771614000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 28281000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 28281000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 912700000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 45772000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 45772000.00
AARTIDRUGS.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 69913000.00
AARTIDRUGS.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 69913000.00